The diabetes drug manufacturer Amylin Pharmaceuticals reported a more serious loss during the second quarter. The development of type 2 diabetes medication Byetta accounted for the loss, the San Diego company said.

Byetta was designed to help control blood sugar amongst patients with type 2 diabetes, whilst offering the unusual and very useful side-effect of weight loss . The drug has been on the market for the last three years, with over 1 million patients being prescribed the drug.

The chief executive of Amylin, Daniel Bradbury, reportedly commented that diabetes drugs with a strong safety profile are in a favourable position. Bradbury was reported as commenting:
"A medicine such as Byetta, which provides powerful, durable glucose control with progressive weight loss and other potential benefits, is uniquely poised to take advantage of the market's growing appreciation for the benefits of our novel therapies."